Repository Home

Summary Statistics

You can filter the data below or go straight to the results. Descriptions of the various cell types we distribute, such as CPLs and LCLs, can be found here. Information on ordering biomaterials can be found here.

Filters

Clear all filters

Disease Distributions

Subjects are grouped into distributions according to the way they were ascertained for their respective studies. This should not be confused with clinical diagnoses. Subjects in the Nicotine Dependence distribution, for example, may or may not be diagnosed with Nicotine Dependence. By default, all distributions are used.

Clinical Diagnoses

The definition of "Affected" depends on the study. The definition for the primary phenotype of each study is shown in the study breakdown section below unless hidden via the option above.

Dependence

Alcohol Dependence:

Cannabis Dependence:

Cocaine Dependence:

Nicotine Dependence:

Opioid Dependence:

Sedative Dependence:

Stimulant Dependence:

Other Dependence:

Abuse

Alcohol Abuse:

Cannabis Abuse:

Cocaine Abuse:

Opioid Abuse:

Sedative Abuse:

Stimulant Abuse:

Other Abuse:

Substance Use Disorders

Opioid Use Disorder:

Cocaine Use Disorder:

Alcohol Use Disorder:

Nicotine Use Disorder:

Cannabis Use Disorder:

Stimulant Use Disorder:

Sedative Use Disorder:

Other Use Disorder:

Multiple Diagnosis Logic*: OR AND

*Example: when OR is selected, if you select both Nicotine and Alcohol dependence you get statistics for the combined set Nicotine-dependent subjects and Alcohol-dependent subjects. When AND is selected, you get statistics for subjects that are both Nicotine-dependent and Alcohol-dependent.

Demographics, Biomaterials and Clinical Instruments

Sex:

Age:Between and

Self-Identified Race/Ethnicity:

Has DNA:

Cell Types:

Min Vials:

Cell Types Logic: OR AND

Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.

Clinical Instrument(s):

Clear all filters

Results

Filters Applied

To share these results with others, including any filters applied, click the box below to copy a link to this page to your clipboard:

Copy URL to Clipboard

Breakdown by Disease Distribution

Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.

Distribution Subjects DNA Available* Plasma LCLs CPLs** Whole Blood
Cannabis 201 199 (99%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 199 (99%)
Cocaine Dependence 2,432 1,555 (64%) 95 ( 4%) 1,145 (47%) 1,475 (61%) 129 ( 5%)
Methamphetamine Dependence 202 201 (100%) 198 (98%) 13 ( 6%) 196 (97%) 4 ( 2%)
Nicotine Dependence 15,593 13,230 (85%) 2,467 (16%) 7,716 (49%) 12,637 (81%) 4,409 (28%)
Opioid Dependence 7,971 6,410 (80%) 2 ( 0%) 3,189 (40%) 4,239 (53%) 3,845 (48%)
Opioid-Cocaine Dependence 7,007 5,343 (76%) 0 ( 0%) 2,159 (31%) 5,195 (74%) 3,134 (45%)
Polysubstance Dependence 4,453 3,465 (78%) 3 ( 0%) 2,004 (45%) 3,365 (76%) 1,814 (41%)
Total 37,859 30,403 (80%) 2,765 ( 7%) 16,226 (43%) 27,107 (72%) 13,534 (36%)

*DNA Available refers to subjects for which DNA is available from at least one of LCLs, CPLs or Whole Blood.

**Note that CPLs are ideal for making iPSCs.

Demographics, DNA and Clinical Instruments

Item Value
Subjects 37,859
DNA Available 30,403 (80%)
Instrument: DSM-IV 23,853 (63%)
Instrument: DSM-V 202 (1%)
Instrument: DSM-III-R 1,028 (3%)
Instrument: Unknown 12,776 (34%)
Females / Males / Unknown 17,790 (47%) / 20,018 (53%) / 51 (0%)
Age Average: 39.9, Min: 11, Max: 111

Self-Identified Race/Ethnicity

Race/Ethnicity Subjects
White Non-Hispanic 18,850 (50%)
African-American 11,211 (30%)
Other 3,369 ( 9%)
White Hispanic 2,105 ( 6%)
Asian 2,033 ( 5%)
Missing 240 ( 1%)
American Indian 48 ( 0%)
Pacific Islander 3 ( 0%)

Cell Types

Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.

Cell Type Subjects Subjects with 2+ Vials 5+ Vials 10+ Vials
LCL 16,226 (43%) 16,220 (43%) 16,182 (43%) 11,429 (30%)
CPL 27,107 (72%) 24,088 (64%) 1 ( 0%) 0 ( 0%)
LCL gDNA 15,785 (42%) 15,602 (41%) 4,033 (11%) 72 ( 0%)
WB gDNA 16,692 (44%) 2,186 ( 6%) 0 ( 0%) 0 ( 0%)
Plasma 2,765 ( 7%) 1,278 ( 3%) 1,263 ( 3%) 15 ( 0%)
Whole Blood 13,534 (36%) 1,944 ( 5%) 2 ( 0%) 0 ( 0%)

Diagnoses

Disease Affected* Unaffected Other
Alcohol Dependence 5,978 (16%) 14,326 (38%) 17,555 (46%)
Cannabis Dependence 4,510 (12%) 13,420 (35%) 19,929 (53%)
Cocaine Dependence 8,307 (22%) 15,135 (40%) 14,417 (38%)
Nicotine Dependence 9,138 (24%) 6,825 (18%) 21,896 (58%)
Opioid Dependence 8,297 (22%) 13,675 (36%) 15,887 (42%)
Other Drug Dependence 1,034 ( 3%) 14,410 (38%) 22,415 (59%)
Sedative Dependence 1,063 ( 3%) 12,189 (32%) 24,607 (65%)
Stimulant Dependence 1,454 ( 4%) 12,335 (33%) 24,070 (64%)
Alcohol Abuse 2,969 ( 8%) 9,010 (24%) 25,880 (68%)
Cannabis Abuse 2,128 ( 6%) 9,373 (25%) 26,358 (70%)
Cocaine Abuse 1,285 ( 3%) 10,324 (27%) 26,250 (69%)
Opioid Abuse 1,202 ( 3%) 10,901 (29%) 25,756 (68%)
Other Drug Abuse 460 ( 1%) 7,832 (21%) 29,567 (78%)
Sedative Abuse 323 ( 1%) 8,385 (22%) 29,151 (77%)
Stimulant Abuse 277 ( 1%) 8,838 (23%) 28,744 (76%)
Alcohol Use Disorder 44 ( 0%) 97 ( 0%) 37,718 (100%)
Cannabis Use Disorder 61 ( 0%) 101 ( 0%) 37,697 (100%)
Cocaine Use Disorder 17 ( 0%) 166 ( 0%) 37,676 (100%)
Nicotine Use Disorder 0 ( 0%) 0 ( 0%) 37,859 (100%)
Opioid Use Disorder 14 ( 0%) 174 ( 0%) 37,671 (100%)
Other Use Disorder 0 ( 0%) 0 ( 0%) 37,859 (100%)
Sedative Use Disorder 15 ( 0%) 159 ( 0%) 37,685 (100%)
Stimulant Use Disorder 202 ( 1%) 0 ( 0%) 37,657 (99%)

*The definition of affected depends on the study and is shown in the study breakdown below (unless hidden via the option above).

Breakdown by NIDA Studies

Cell type descriptions can be found here. Note that CPLs are ideal for making iPSCs.

Cannabis Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
32 Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053 Kevin Gray DSM Cannabis Dependence 201 199 (99%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 199 (99%)
Total 201 199 (99%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 199 (99%)
Cocaine Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
7 An Introduction to the Family Study of Cocaine Laura Bierut DSM Cocaine Dependence 1,914 1,049 (55%) 95 ( 5%) 852 (45%) 990 (52%) 103 ( 5%)
13 Genetics of Cocaine Induced Psychosis Joseph F. Cubells DSM Cocaine Dependence 238 230 (97%) 0 ( 0%) 229 (96%) 214 (90%) 1 ( 0%)
29 Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048 David A. Nielsen DSM Cocaine Dependence 280 276 (99%) 0 ( 0%) 64 (23%) 271 (97%) 25 ( 9%)
Total 2,432 1,555 (64%) 95 ( 4%) 1,145 (47%) 1,475 (61%) 129 ( 5%)
Methamphetamine Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
37 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068 Madhukar Trivedi 202 201 (100%) 198 (98%) 13 ( 6%) 196 (97%) 4 ( 2%)
Total 202 201 (100%) 198 (98%) 13 ( 6%) 196 (97%) 4 ( 2%)
Nicotine Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
NicSNP The NicSNP Study Laura Bierut FTND >= 4 1,927 1,927 (100%) 515 (27%) 1,340 (70%) 1,880 (98%) 773 (40%)
2 Mapping Susceptibility Genes for Nicotine Dependence Ming D. Li DSM Nicotine Dependence or FTND>=4 2,803 1,962 (70%) 0 ( 0%) 1,961 (70%) 1,835 (65%) 0 ( 0%)
6 The Genetics of Vulnerability to Nicotine Pamela Madden DSM Nicotine Dependence or FTND>=4 3,446 2,344 (68%) 0 ( 0%) 2,330 (68%) 2,156 (63%) 30 ( 1%)
9 Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics Consortium Ovide Pomerleau DSM Nicotine Dependence or FTND>=4 or 5 cigs/day for 5 years and current 6 months 1,565 1,540 (98%) 0 ( 0%) 607 (39%) 1,502 (96%) 887 (57%)
10 Pharmacokinetics of Nicotine in Twins Gary Swan DSM Nicotine Dependence or FTND>=4 124 62 (50%) 0 ( 0%) 62 (50%) 60 (48%) 0 ( 0%)
15 Nicotine Dependence Laura Bierut DSM Nicotine Dependence or FTND>=4 2,146 1,813 (84%) 876 (41%) 854 (40%) 1,761 (82%) 1,131 (53%)
16 Nicotine Dependence Mark Leppert DSM Nicotine Dependence or FTND>=4 917 917 (100%) 2 ( 0%) 359 (39%) 821 (90%) 535 (58%)
27 The Genetic Study of Nicotine Dependence in African Americans (AAND) Laura Bierut DSM Nicotine Dependence or FTND>=4 1,792 1,792 (100%) 206 (11%) 194 (11%) 1,753 (98%) 1,032 (58%)
35 Genetically Informative Smoking Cessation Trial Li-Shiun Chen Active smoking (Cigarettes Per Day [CPD] ≥5) and exhaled Carbon Monoxide [CO] ≥8 ppm 873 873 (100%) 868 (99%) 9 ( 1%) 869 (100%) 21 ( 2%)
Total 15,593 13,230 (85%) 2,467 (16%) 7,716 (49%) 12,637 (81%) 4,409 (28%)
Opioid Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
3 Molecular Genetics of Heroin Dependence in China Ming Tsuang DSM Opioid Dependence 1,929 1,099 (57%) 0 ( 0%) 1,097 (57%) 3 ( 0%) 222 (12%)
5 Addictions, Genotypes, Polymorphisms, and Function Mary Jeanne Kreek DSM Opioid Dependence 1,751 1,751 (100%) 2 ( 0%) 768 (44%) 1,707 (97%) 997 (57%)
14 Genome-Wide Analysis for Addiction Susceptibility Genes Herb Lachman DSM Opioid Dependence 1,405 693 (49%) 0 ( 0%) 598 (43%) 640 (46%) 116 ( 8%)
17 Opioid Dependence Wade Berrettini DSM Opioid Dependence 204 200 (98%) 0 ( 0%) 70 (34%) 191 (94%) 99 (49%)
18 Opioid Dependence: Candidate Genes and G x E Effects Elliot Nelson DSM Opioid Dependence 1,896 1,882 (99%) 0 ( 0%) 500 (26%) 954 (50%) 1,627 (86%)
24 START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START) Wade Berrettini DSM Opioid Dependence 786 785 (100%) 0 ( 0%) 156 (20%) 744 (95%) 784 (100%)
Total 7,971 6,410 (80%) 2 ( 0%) 3,189 (40%) 4,239 (53%) 3,845 (48%)
Opioid-Cocaine Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
1 Genetics of Opioid Dependence Joel Gelernter DSM Opioid or Cocaine Dependence 6,511 4,847 (74%) 0 ( 0%) 2,118 (33%) 4,706 (72%) 2,777 (43%)
20 Innovative Approaches for Cocaine Pharmacotherapy Henry Kranzler DSM Opioid or Cocaine Dependence 496 496 (100%) 0 ( 0%) 41 ( 8%) 489 (99%) 357 (72%)
Total 7,007 5,343 (76%) 0 ( 0%) 2,159 (31%) 5,195 (74%) 3,134 (45%)
Polysubstance Dependence
Study Name PI Definition of Affected N DNA Available* Plasma LCLs CPLs** Whole Blood
11 Adolescent Drug Dependence John Hewitt DSM Opioid, Cocaine, Cannabis, Stimulant, Sedative, or other dependence 2,403 1,589 (66%) 1 ( 0%) 1,084 (45%) 1,521 (63%) 502 (21%)
12 Substance Abuse and the Dopamine System Genes Michael M. Yanyukov DSM Opioid, Cocaine, Cannabis, Stimulant, Sedative, or other dependence 600 470 (78%) 0 ( 0%) 406 (68%) 449 (75%) 0 ( 0%)
19 Epidemiological Study of Substance Abuse Rob Philibert DSM Opioid, Cocaine, Cannabis, Stimulant, Sedative, or other dependence 562 520 (93%) 1 ( 0%) 485 (86%) 510 (91%) 430 (77%)
23 Substance Use Disorder Liability: Candidate Gene System Michael M. Vanyukov DSM Opioid, Cocaine, Cannabis, Stimulant, Sedative, or other dependence 888 886 (100%) 1 ( 0%) 29 ( 3%) 885 (100%) 882 (99%)
Total 4,453 3,465 (78%) 3 ( 0%) 2,004 (45%) 3,365 (76%) 1,814 (41%)

*DNA Available refers to subjects for which DNA is available from at least one of LCLs, CPLs or Whole Blood.

**Note that CPLs are ideal for making iPSCs.

cell_file version: 2024-09-10-11-54